BLISS GVS PHARMA LTD.



May 02, 2024

To

The Manager, Listing Department National Stock Exchange of India Ltd.

Plot no. C/1 G Block,

Bandra-Kurla Complex, Bandra (East),

Mumbai- 400 051 Symbol: **BLISSGVS** To

The General Manager, Listing Department

BSE Limited

Phiroze Jeejeebhoy Towers,

Dalal Street, Mumbai- 400 001 Scrip Code: **506197**

Dear Sir/Madam,

Subject: Outcome of Board Meeting held on Thursday, May 02, 2024

We would like to inform you that, the Board Meeting of the Company was held today i.e. on Thursday, May 02, 2024 at the registered office of the Company. In pursuant to Regulation 30 and Regulation 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board has considered and approved the following matters amongst others:

- 1. The Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2024 along with the audit report of the auditors. A copy of the said financials and Audit Reports is enclosed herewith as 'Annexure-1'.
- 2. Declaration of unmodified opinion for annual audited standalone and consolidated financial results for the year ended March 31, 2024 in accordance with Regulation 33(3)(d) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular no. CIR/CFD/CMD/56/2016 dated May 27, 2016 is enclosed herewith as 'Annexure 2';
- 3. Recommended Final Dividend of 50% i.e. 50 Paisa per equity share on the face value of Rs. 1/- each for the financial year ended March 31, 2024, subject to the approval of the shareholders in the forthcoming 39th Annual General Meeting of the Company ('39th AGM');
- Re-appointment of M/s. BDO India LLP, Chartered Accountant having LLP Registration No. AAB-7880 as Internal Auditor of the Company for the financial year 2024-25. The brief profile of the internal auditor is enclosed herewith as 'Annexure-3';
- 5. Re-appointment of M/s. AVS & Associates, Practicing Company Secretaries, as Secretarial Auditor of the Company for the financial year 2024-2025. The brief profile of the Secretarial auditor is enclosed herewith as 'Annexure-4';
- 6. Re-appointment of Mr. Gagan Harsh Sharma (DIN: 07939421) as the Managing Director of

Regd. Office: 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai - 400 072, INDIA.

TEL.: (+91) (22) 42160000/ 28505387 • FAX.: (+91) (22) 28563930,

Email: info@blissgvs.com • Website: www.blissgvs.com • CIN - L24230MH1984PLC034771

Factory: Plot No. 10, 11 & 12, Survey No. 38/1, Dewan Udyog Nagar, Aliyali Village, Tal. & Dist. Palghar - 401 404.

Tel. (+91) (02525) 252713 • Fax: (+91) (02525) 255257. • Email: factory@blissgvs.com

BLISS GVS PHARMA LTD.



the Company for a period of Three years with effect from May 11, 2024 to May 10, 2027, subject to the approval of members in the ensuing 39th AGM. The brief profile is enclosed herewith as 'Annexure-5'. Further, we would like to state that as per the requirement of Circular No. LIST/COMP/14/2018-19 dated June 20, 2018 w.r.t Enforcement of SEBI order regarding Appointment of Directors by Listed Companies, the Board of Directors and Nomination and Remuneration Committee while considering the appointment of Mr. Gagan Harsh Sharma as Managing Director of the Company have verified and confirmed from her that he is not debarred from holding the office as a Director pursuant to any SEBI order or any other such authority. Accordingly, we hereby affirm that Mr. Gagan Harsh Sharma, being appointed as Managing Director is not debarred from holding the office of Director by virtue of any SEBI order or any other such Authority.

- 7. Re-appointment of Dr. Vibha Gagan Sharma (DIN: 02307289) as a Whole-Time Director of the Company for a period of Three years with effect from January 27, 2025 to January 26, 2028, subject to the approval of members in the ensuing 39th AGM. The brief profile is enclosed herewith as 'Annexure-6'. Further, we would like to state that as per the requirement of Circular No. LIST/COMP/14/2018-19 dated June 20, 2018 w.r.t Enforcement of SEBI order regarding Appointment of Directors by Listed Companies, the Board of Directors and Nomination and Remuneration Committee while considering the appointment of Dr. Vibha Gagan Sharma as Whole-Time Director of the Company have verified and confirmed from her that she is not debarred from holding the office as a Director pursuant to any SEBI order or any other such authority. Accordingly, we hereby affirm that Dr. Vibha Gagan Sharma, being appointed as Whole-Time Director, is not debarred from holding the office of Director by virtue of any SEBI order or any other such Authority.
- 8. Re-appointment Mrs. Shruti Vishal Rao (DIN: 00731501) as a Whole-Time Director of the Company for a period of Three years with effect from April 01, 2025 to March 31, 2028, subject to the approval of members in the ensuing 39th AGM. The brief profile is enclosed herewith as' Annexure-7'. Further, we would like to state that as per the requirement of Circular No. LIST/COMP/14/2018-19 dated June 20, 2018 w.r.t Enforcement of SEBI order regarding Appointment of Directors by Listed Companies, the Board of Directors and Nomination and Remuneration Committee while considering the appointment of Mrs. Shruti Vishal Rao as Whole-Time Director of the Company have verified and confirmed from her that she is not debarred from holding the office as a Director pursuant to any SEBI order or any other such authority. Accordingly, we hereby affirm that Mrs. Shruti Vishal Rao, being appointed as Whole-Time Director, is not debarred from holding the office of Director by virtue of any SEBI order or any other such Authority.
- 9. Appointment of Mrs. Shilpa Vinodkumar Bhatia (DIN:08695595) as Non-Executive Independent Woman Director of the Company for a period of Five years with effect from February 11, 2025 to February 10, 2030, subject to the approval of members in the ensuing 39th AGM. The brief profile of Mrs. Shilpa Vinodkumar Bhatia is enclosed herewith as

Regd. Office: 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai - 400 072, INDIA.

TEL.: (+91) (22) 42160000/ 28505387 • FAX.: (+91) (22) 28563930,

Email: info@blissgvs.com • Website: www.blissgvs.com • CIN - L24230MH1984PLC034771

Factory: Plot No. 10, 11 & 12, Survey No. 38/1, Dewan Udyog Nagar, Aliyali Village, Tal. & Dist. Palghar - 401 404.

Tel. (+91) (02525) 252713 • Fax: (+91) (02525) 255257. • Email: factory@blissgvs.com

BLISS GVS PHARMA LTD.



'Annexure-8'; Further, we would like to state that as per requirement of Circular No. LIST/COMP/14/2018-19 dated June 20, 2018 w.r.t Enforcement of SEBI order regarding Appointment of Directors by Listed Companies, the Board of Directors and Nomination and Remuneration Committee while considering the appointment of Mrs. Shilpa Vinodkumar Bhatia as Independent Director of the Company have verified and confirmed from her that she is not debarred from holding the office as a Director pursuant to any SEBI order or any other such authority. Accordingly, we hereby affirm that Mrs. Shilpa Vinodkumar Bhatia, being appointed as Independent Director, is not debarred from holding the office of Director by virtue of any SEBI order or any other such Authority.

- 10. Pursuant to Section 188 of the Companies Act, 2013 and based on the recommendation of the Nomination and Remuneration Committee and Audit Committee and subject to the approval of the shareholders of the Company, the Board extended the employment contract of Mr. Vishal Vijay Rao Vice President for holding office or place of profit as an employee of the Company in the Senior Managerial capacity. The brief profile of Mr. Vishal Vijay Rao is enclosed herewith as 'Annexure-9'
- 11.39th Annual General Meeting ("39th AGM") of the Company for the Financial Year 2023-2024 has been scheduled to be held on Thursday, 25th July, 2024 through Video Conferencing ('VC') / Other Audio Visual Means ('OAVM') facility pursuant to Circular No.14 / 2020 dated April 8, 2020, Circular No. 17 / 2020 dated April 13, 2020 and Circular No. 20 / 2020 dated May 5, 2020, read with Circular No. 21 / 2021 dated December 14, 2021, Circular No. 02 / 2021 dated January 13, 2021, Circular No. 19 / 2021 dated December 8, 2021, Circular No. 02 / 2022 dated May 05, 2022, General Circular No. 10 / 2022 dated December 2022 and General Circular No. 09/2023 dated September 25, 2023 issued by the Ministry of Corporate Affairs ("MCA Circulars") which does not require physical presence of members at a common venue. The deemed venue for the 39th AGM shall be the Registered Office of the Company.

The Board of Directors meeting commenced at 16:00 and concluded at 21:45.

Kindly take the above information on your record and acknowledge it.

Thanking you. Yours Faithfully,

For Bliss GVS Pharma Limited

Aditi Bhatt Company Secretary

Encl: As above

Regd. Office: 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai - 400 072, INDIA.

TEL.: (+91) (22) 42160000/ 28505387 • FAX.: (+91) (22) 28563930,

Email: info@blissgvs.com • Website: www.blissgvs.com • CIN - L24230MH1984PLC034771

Factory: Plot No. 10, 11 & 12, Survey No. 38/1, Dewan Udyog Nagar, Aliyali Village, Tal. & Dist. Palghar - 401 404.

Tel. (+91) (02525) 252713 • Fax: (+91) (02525) 255257. • Email: factory@blissgvs.com